Latest News
Statement from Breast Cancer Aotearoa Coalition
Wiki Mulholland should be anticipating her forty-fourth birthday tomorrow. A day that was always a family celebration with her treasured and…
The Breast Cancer Aotearoa Coalition (BCAC) fully supports a petition launched recently by Breast Cancer Foundation NZ (BCFNZ) urging the Government to put resource into finding women who have missed their mammograms and restoring New Zealand’s breast screening programme.
…
Most people know October is recognised as Breast Cancer Awareness Month but today, 13th October, is also Metastatic Breast Cancer Day. This day is an opportunity to acknowledge and raise awareness about the hundreds of New Zealanders living with metastatic breast cancer.
…
COVID-19 has impacted life in so many ways: our family life, our social life, our work life. We’re all limiting our interactions with others to reduce the risk of contracting and spreading the virus.
Now is a great time to give dragon boating a go at the start of the new season.
The Busting with Life Dragon Boat Team, based in Auckland,…
Following the Government’s announcement in early March 2021 that it would conduct an independent review into PHARMAC, Breast Cancer Aotearoa Coalition (BCAC) has recently made a submission to the independent panel, chaired by consumer advocate Sue Chetwin.
Do you want to be part of an organisation that truly makes a difference in your community? Sweet Louise is looking for a motivated, committed, compassionate individual to join our team in Auckland as part of the coordinator network.
About Sweet Louise
Sweet Louise is the only charitable organisation in New Zealand dedicated to supporting women and men living with incurable breast cancer. We are here to help those living with incurable breast cancer to live as…
This clinical trial is investigating the efficacy and safety of GDC-9545 combined with palbociclib compared with Letrozole combined with palbociclib in patients with oestrogen receptor positive, HER2-negative, locally advanced or metastatic breast cancer.
…
This study will evaluate the efficacy and safety of GDC-0077 plus palbociclib and fulvestrant versus a placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer.
…
